CD274 and breast carcinoma: While immune checkpoint blockade such as anti-PD-1 and anti-PD-L1 treatment proved to be impressively effective across a wide range of cancer types (37–39) only a small fraction of breast cancer patients benefits from anti-PD-(L)1 monotherapy (5, 40).